Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 710

1.

The importance of greater speed in drug development for advanced malignancies.

Stewart DJ, Stewart AA, Wheatley-Price P, Batist G, Kantarjian HM, Schiller J, Clemons M, Bradford JP, Gillespie L, Kurzrock R.

Cancer Med. 2018 Mar 30. doi: 10.1002/cam4.1454. [Epub ahead of print]

2.

TP53 mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) [18F] fluorodeoxyglucose (18F-FDG PET).

Chang GH, Kurzrock R, Tran L, Schwaederle M, Hoh CK.

Oncotarget. 2018 Feb 16;9(18):14306-14310. doi: 10.18632/oncotarget.24508. eCollection 2018 Mar 6.

3.

JAK2 V617F mutation in plasma cell-free DNA preceding clinically overt myelofibrosis: Implications for early diagnosis.

Choi MY, Kato S, Wang HY, Lin JH, Lanman RB, Kurzrock R.

Cancer Biol Ther. 2018 Mar 22:1-17. doi: 10.1080/15384047.2018.1450120. [Epub ahead of print]

PMID:
29565699
4.

Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial.

Maitland ML, Piha-Paul S, Falchook G, Kurzrock R, Nguyen L, Janisch L, Karovic S, McKee M, Hoening E, Wong S, Munasinghe W, Palma J, Donawho C, Lian GK, Ansell P, Ratain MJ, Hong D.

Br J Cancer. 2018 Apr;118(8):1042-1050. doi: 10.1038/s41416-018-0020-2. Epub 2018 Mar 19.

PMID:
29551775
5.

Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma.

Ikeda S, Tsigelny IF, Skjevik ÅA, Kono Y, Mendler M, Kuo A, Sicklick JK, Heestand G, Banks KC, Talasaz A, Lanman RB, Lippman S, Kurzrock R.

Oncologist. 2018 Feb 27. pii: theoncologist.2017-0479. doi: 10.1634/theoncologist.2017-0479. [Epub ahead of print]

PMID:
29487225
6.

Analysis of Tissue and Circulating Tumor DNA by Next Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics.

Ikeda S, Lim JS, Kurzrock R.

Mol Cancer Ther. 2018 Feb 26. pii: molcanther.0604.2017. doi: 10.1158/1535-7163.MCT-17-0604. [Epub ahead of print]

PMID:
29483209
7.

Challenging Standard-of-Care Paradigms in the Precision Oncology Era.

Subbiah V, Kurzrock R.

Trends Cancer. 2018 Feb;4(2):101-109. doi: 10.1016/j.trecan.2017.12.004. Epub 2018 Jan 12. Review.

PMID:
29458960
8.

Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies.

Goodman AM, Kato S, Cohen PR, Boichard A, Frampton G, Miller V, Stephens PJ, Daniels GA, Kurzrock R.

Oncoimmunology. 2017 Dec 22;7(3):e1404217. doi: 10.1080/2162402X.2017.1404217. eCollection 2018.

9.

Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus.

Schrock AB, Pavlick D, Klempner SJ, Chung JH, Forcier B, Welsh A, Young L, Leyland-Jones B, Bordoni R, Carvajal RD, Chao J, Kurzrock R, Sicklick JK, Ross JS, Stephens PJ, Devoe C, Braiteh F, Ali SM, Miller VA.

Clin Cancer Res. 2018 Apr 15;24(8):1881-1890. doi: 10.1158/1078-0432.CCR-17-3103. Epub 2018 Jan 23.

PMID:
29363525
10.

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.

Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R.

J Clin Oncol. 2018 Feb 20;36(6):536-542. doi: 10.1200/JCO.2017.75.3780. Epub 2018 Jan 10.

PMID:
29320312
11.

Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors.

Jardim DL, de Melo Gagliato D, Giles FJ, Kurzrock R.

Clin Cancer Res. 2018 Apr 15;24(8):1785-1794. doi: 10.1158/1078-0432.CCR-17-1970. Epub 2017 Dec 6. Review.

PMID:
29212781
12.

Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients.

Schwaederle M, Krishnamurthy N, Daniels GA, Piccioni DE, Kesari S, Fanta PT, Schwab RB, Patel SP, Parker BA, Kurzrock R.

Cancer. 2018 Mar 15;124(6):1288-1296. doi: 10.1002/cncr.31175. Epub 2017 Dec 6.

13.

Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining "Actionability" of a Molecular Lesion and Patient Management Support.

Chae YK, Pan AP, Davis AA, Patel SP, Carneiro BA, Kurzrock R, Giles FJ.

Mol Cancer Ther. 2017 Dec;16(12):2645-2655. doi: 10.1158/1535-7163.MCT-17-0597. Review.

PMID:
29203694
14.

Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors.

Krishnamurthy N, Kurzrock R.

Cancer Treat Rev. 2018 Jan;62:50-60. doi: 10.1016/j.ctrv.2017.11.002. Epub 2017 Nov 13. Review.

PMID:
29169144
15.

Core Clinical Data Elements for Cancer Genomic Repositories: A Multi-stakeholder Consensus.

Conley RB, Dickson D, Zenklusen JC, Al Naber J, Messner DA, Atasoy A, Chaihorsky L, Collyar D, Compton C, Ferguson M, Khozin S, Klein RD, Kotte S, Kurzrock R, Lin CJ, Liu F, Marino I, McDonough R, McNeal A, Miller V, Schilsky RL, Wang LI.

Cell. 2017 Nov 16;171(5):982-986. doi: 10.1016/j.cell.2017.10.032.

PMID:
29149611
16.

Molecular Tumor Boards: Realizing Precision Oncology Therapy.

Patel M, Kato SM, Kurzrock R.

Clin Pharmacol Ther. 2018 Feb;103(2):206-209. doi: 10.1002/cpt.920. Epub 2017 Nov 14.

PMID:
29134641
17.

The Mutational Landscape of Gastrointestinal Malignancies as Reflected by Circulating Tumor DNA.

Riviere P, Fanta PT, Ikeda S, Baumgartner J, Heestand GM, Kurzrock R.

Mol Cancer Ther. 2018 Jan;17(1):297-305. doi: 10.1158/1535-7163.MCT-17-0360. Epub 2017 Nov 13.

PMID:
29133621
18.

Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study.

Tsimberidou AM, Hong DS, Ye Y, Cartwright C, Wheler JJ, Falchook GS, Naing A, Fu S, Piha-Paul S, Janku F, Meric-Bernstam F, Hwu P, Kee B, Kies MS, Broaddus R, Mendelsohn J, Hess KR, Kurzrock R.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00002. Epub 2017 Sep 8.

19.

Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours.

Schöffski P, Gordon M, Smith DC, Kurzrock R, Daud A, Vogelzang NJ, Lee Y, Scheffold C, Shapiro GI.

Eur J Cancer. 2017 Nov;86:296-304. doi: 10.1016/j.ejca.2017.09.011. Epub 2017 Oct 20.

20.

Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach.

Kato S, Kurasaki K, Ikeda S, Kurzrock R.

Oncologist. 2018 Feb;23(2):171-178. doi: 10.1634/theoncologist.2017-0199. Epub 2017 Oct 16.

PMID:
29038235
21.

Genomics of Immunotherapy-Associated Hyperprogressors-Response.

Kato S, Kurzrock R.

Clin Cancer Res. 2017 Oct 15;23(20):6376. doi: 10.1158/1078-0432.CCR-17-1990. No abstract available.

PMID:
29030333
22.

Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities.

Costa R, Costa RB, Talamantes SM, Helenoswki I, Carneiro BA, Chae YK, Gradishar WJ, Kurzrock R, Giles FJ.

Oncotarget. 2017 Jun 29;8(40):67782-67789. doi: 10.18632/oncotarget.18847. eCollection 2017 Sep 15.

23.

Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy.

Khagi Y, Goodman AM, Daniels GA, Patel SP, Sacco AG, Randall JM, Bazhenova LA, Kurzrock R.

Clin Cancer Res. 2017 Oct 1;23(19):5729-5736. doi: 10.1158/1078-0432.CCR-17-1439.

PMID:
28972084
24.

Next-Generation Sequencing in the Clinical Setting Clarifies Patient Characteristics and Potential Actionability.

Bieg-Bourne CC, Millis SZ, Piccioni DE, Fanta PT, Goldberg ME, Chmielecki J, Parker BA, Kurzrock R.

Cancer Res. 2017 Nov 15;77(22):6313-6320. doi: 10.1158/0008-5472.CAN-17-1569. Epub 2017 Sep 22.

PMID:
28939679
25.

Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns.

Nikanjam M, Patel H, Kurzrock R.

Oncoimmunology. 2017 Jun 28;6(8):e1338997. doi: 10.1080/2162402X.2017.1338997. eCollection 2017.

PMID:
28920006
26.

The biology of Hepatocellular carcinoma: implications for genomic and immune therapies.

Khemlina G, Ikeda S, Kurzrock R.

Mol Cancer. 2017 Aug 30;16(1):149. doi: 10.1186/s12943-017-0712-x. Review.

27.

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.

Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R.

Mol Cancer Ther. 2017 Nov;16(11):2598-2608. doi: 10.1158/1535-7163.MCT-17-0386. Epub 2017 Aug 23.

PMID:
28835386
28.

BRAF mutation as a novel driver of eosinophilic cystitis.

Choi MY, Tsigelny IF, Boichard A, Skjevik ÅA, Shabaik A, Kurzrock R.

Cancer Biol Ther. 2017 Sep 2;18(9):655-659. doi: 10.1080/15384047.2017.1360449. Epub 2017 Aug 22.

PMID:
28829677
29.

Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing.

Schwaederle M, Chattopadhyay R, Kato S, Fanta PT, Banks KC, Choi IS, Piccioni DE, Ikeda S, Talasaz A, Lanman RB, Bazhenova L, Kurzrock R.

Cancer Res. 2017 Oct 1;77(19):5419-5427. doi: 10.1158/0008-5472.CAN-17-0885. Epub 2017 Aug 14.

PMID:
28807936
30.
31.

A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma.

Vergote IB, Smith DC, Berger R, Kurzrock R, Vogelzang NJ, Sella A, Wheler J, Lee Y, Foster PG, Weitzman R, Buckanovich RJ.

Eur J Cancer. 2017 Sep;83:229-236. doi: 10.1016/j.ejca.2017.06.018. Epub 2017 Jul 26.

32.

Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act.

Kehl KL, Fullmer CP, Fu S, George GC, Hess KR, Janku F, Karp DD, Kato S, Kizer CK, Kurzrock R, Naing A, Pant S, Piha-Paul SA, Subbiah V, Tsimberidou AM, Hong DS.

Clin Cancer Res. 2017 Jul 20. doi: 10.1158/1078-0432.CCR-16-3027. [Epub ahead of print]

PMID:
28729355
33.

Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients.

Heestand GM, Schwaederle M, Gatalica Z, Arguello D, Kurzrock R.

Eur J Cancer. 2017 Sep;83:80-87. doi: 10.1016/j.ejca.2017.06.019. Epub 2017 Jul 17.

34.

Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take Credit.

Kato S, Subbiah V, Kurzrock R.

J Natl Compr Canc Netw. 2017 Jul;15(7):863-866. doi: 10.6004/jnccn.2017.0127. No abstract available.

PMID:
28687573
35.

Next Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients with Lymphoid Malignancies.

Goodman AM, Choi M, Wieduwilt M, Mulroney C, Costello C, Frampton G, Miller V, Kurzrock R.

JCO Precis Oncol. 2017 Jun;1. doi: 10.1200/PO.16.00004. Epub 2017 Apr 27.

36.

Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary.

Kato S, Krishnamurthy N, Banks KC, De P, Williams K, Williams C, Leyland-Jones B, Lippman SM, Lanman RB, Kurzrock R.

Cancer Res. 2017 Aug 15;77(16):4238-4246. doi: 10.1158/0008-5472.CAN-17-0628. Epub 2017 Jun 22.

PMID:
28642281
37.

Polycystic ovary syndrome in men.

Cohen PR, Kurzrock R.

Med Hypotheses. 2017 Jun;103:64. doi: 10.1016/j.mehy.2017.04.010. Epub 2017 Apr 20. No abstract available.

PMID:
28571814
38.

Debunking the Delusion That Precision Oncology Is an Illusion.

Subbiah V, Kurzrock R.

Oncologist. 2017 Aug;22(8):881-882. doi: 10.1634/theoncologist.2017-0040. Epub 2017 May 26. No abstract available.

PMID:
28550030
39.
40.

Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma.

Schwaederlé MC, Patel SP, Husain H, Ikeda M, Lanman RB, Banks KC, Talasaz A, Bazhenova L, Kurzrock R.

Clin Cancer Res. 2017 Sep 1;23(17):5101-5111. doi: 10.1158/1078-0432.CCR-16-2497. Epub 2017 May 24.

PMID:
28539465
41.

Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology.

Husain H, Nykin D, Bui N, Quan D, Gomez G, Woodward B, Venkatapathy S, Duttagupta R, Fung E, Lippman SM, Kurzrock R.

Mol Cancer Ther. 2017 May;16(5):948-955. doi: 10.1158/1535-7163.MCT-16-0436.

PMID:
28468865
42.

Dosing Three-Drug Combinations That Include Targeted Anti-Cancer Agents: Analysis of 37,763 Patients.

Nikanjam M, Liu S, Yang J, Kurzrock R.

Oncologist. 2017 May;22(5):576-584. doi: 10.1634/theoncologist.2016-0357. Epub 2017 Apr 19.

PMID:
28424323
43.

Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine.

Husain H, Melnikova VO, Kosco K, Woodward B, More S, Pingle SC, Weihe E, Park BH, Tewari M, Erlander MG, Cohen E, Lippman SM, Kurzrock R.

Clin Cancer Res. 2017 Aug 15;23(16):4716-4723. doi: 10.1158/1078-0432.CCR-17-0454. Epub 2017 Apr 18.

44.

High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations.

Boichard A, Tsigelny IF, Kurzrock R.

Oncoimmunology. 2017 Jan 31;6(3):e1284719. doi: 10.1080/2162402X.2017.1284719. eCollection 2017.

45.

Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma.

Subbiah V, Meyer C, Zinner R, Meric-Bernstam F, Zahurak ML, O'Connor A, Roszik J, Shaw K, Ludwig JA, Kurzrock R, Azad NA.

Clin Cancer Res. 2017 Aug 1;23(15):4027-4034. doi: 10.1158/1078-0432.CCR-17-0272. Epub 2017 Apr 4. Erratum in: Clin Cancer Res. 2018 Jan 15;24(2):500-501.

46.

Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.

Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R.

Clin Cancer Res. 2017 Aug 1;23(15):4242-4250. doi: 10.1158/1078-0432.CCR-16-3133. Epub 2017 Mar 28.

PMID:
28351930
47.

Systematic analysis of early phase clinical studies for patients with breast cancer: Inclusion of patients with brain metastasis.

Costa R, Gill N, Rademaker AW, Carneiro BA, Chae YK, Kumthekar P, Gradishar WJ, Kurzrock R, Giles FJ.

Cancer Treat Rev. 2017 Apr;55:10-15. doi: 10.1016/j.ctrv.2017.02.006. Epub 2017 Feb 22. Review.

PMID:
28279895
48.

JAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease.

Patel M, Ikeda S, Pilat SR, Kurzrock R.

JAMA Dermatol. 2017 May 1;153(5):449-452. doi: 10.1001/jamadermatol.2016.5554.

PMID:
28241173
49.

Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.

Mita M, Fu S, Piha-Paul SA, Janku F, Mita A, Natale R, Guo W, Zhao C, Kurzrock R, Naing A.

Invest New Drugs. 2017 Oct;35(5):616-626. doi: 10.1007/s10637-017-0442-3. Epub 2017 Feb 13.

PMID:
28194539
50.

Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer.

Husain H, Scur M, Murtuza A, Bui N, Woodward B, Kurzrock R.

Mol Cancer Ther. 2017 Feb;16(2):265-272. doi: 10.1158/1535-7163.MCT-16-0105. Review.

Supplemental Content

Loading ...
Support Center